Document is current
Any future updates will be listed below
-
Authors
Osaki, M. https://orcid.org/0000-0002-0315-0616
Okuda, R.
Saeki, Y.
Okano, T.
Tsuda, K.
Nakamura, T.
Morio, Y.
Nagashima, H.
Hagino, H.
- License Information
-
More Information
Article History
Received: 11 October 2020
Accepted: 4 January 2021
First Online: 23 January 2021
Compliance with ethical standards
:
: MO, RO, YS, KT, TN, YM, and TO declare that they have no conflict of interest. HN received lecture fees or grants outside the submitted work from Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Pfizer Inc.; Taisho Toyama Pharmaceutical Co., Ltd.; Teijin Pharma Co., Ltd; Takeda Pharmaceutical Co., Ltd.; Kaken Pharmaceutical Co., Ltd.; Shionogi & Co., Ltd.; Nippon Zoki Pharmaceutical Co., Ltd.; Eli Lilly Japan Co., Ltd.; Hisamitsu Pharmaceutical Co., Ltd. MSD KK, and HH received lecture fees or grants outside the submitted work from Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Astellas Amgen Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Ono Pharmaceutical Co., Ltd.; Pfizer Inc.; Taisho Toyama Pharmaceutical Co., Ltd.; Teijin Pharma Co., Ltd; and UCB Japan Co., Ltd.
: The study was approved by the ethics research committee at the Faculty of Medicine, Tottori University (No 2631) or each ethics committee of the sites that participated in the study.
: Written informed consent was obtained from all patients before participating in this study.
: Written consent for participation and consent for publication were obtained from all patients at the time of study enrollment.
